We are live on ! Find out more
CC

Caxton Corporation Portfolio holdings

AUM $4.02M
1-Year Est. Return 256.08%
This Fund
S&P 500
This Quarter Est. Return
+95.33%
1 Year Est. Return
+256.08%
3 Year Est. Return
+777.99%
5 Year Est. Return
+744.68%
10 Year Est. Return
+18,621.85%
AUM
$22.9M
AUM Growth
+$13M
Cap. Flow
+$3.29M
Cap. Flow %
14.4%
Top 10 Hldgs %
99.83%
Holding
12
New
1
Increased
4
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
RZLT icon
Rezolute
RZLT
+$2.55M
2
GLD icon
SPDR Gold Trust
GLD
+$744K
3
CMPX icon
Compass Therapeutics
CMPX
+$31.7K
4
SABS icon
SAB Biotherapeutics
SABS
+$24.7K
5
BRK.B icon
Berkshire Hathaway Class B
BRK.B
+$9.2K

Top Sells

Rank Stock Value
1
DFTX
Definium Therapeutics
DFTX
+$65.9K

Sector Composition

Rank Sector Weight
1 Healthcare 87.24%
2 Financials 1.43%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RZLT icon
1
Rezolute
RZLT
$421M
$18.7M 81.7%
1,986,818
+382,832
+24% +$2.55M
GLD icon
2
SPDR Gold Trust
GLD
$130B
$2.59M 11.33%
7,286
+2,334
+47% +$744K
BRK.B icon
3
Berkshire Hathaway Class B
BRK.B
$1.06T
$327K 1.43%
651
+19
+3% +$9.2K
DFTX
4
Definium Therapeutics
DFTX
$5.85B
$318K 1.39%
27,011
-7,062
-21% -$65.9K
ELVN icon
5
Enliven Therapeutics
ELVN
$3.63B
$268K 1.17%
13,097
– –
CMPX icon
6
Compass Therapeutics
CMPX
$378M
$187K 0.82%
53,503
+10,038
+23% +$31.7K
BCAX
7
Bicara Therapeutics
BCAX
$1.81B
$173K 0.76%
10,941
– –
KYTX icon
8
Kyverna Therapeutics
KYTX
$452M
$138K 0.6%
22,981
– –
LXEO icon
9
Lexeo Therapeutics
LXEO
$358M
$115K 0.5%
17,332
– –
IKT icon
10
Inhibikase Therapeutics
IKT
$316M
$26.6K 0.12%
16,393
– –
SABS icon
11
SAB Biotherapeutics
SABS
$280M
$22K 0.1%
+10,935
New +$24.7K
CNTX icon
12
Context Therapeutics
CNTX
$56.5M
$17.8K 0.08%
18,403
– –

Similar funds

PCM
Pathway Capital Management Irvine, California $4.3M AUM 62.8% 1-Year Est. Return
EAMS
Eurizon Asset Management Slovakia Bratislava $3.4M AUM
RCP
RPM Capital Partners New York $3.34M AUM 43.17% 1-Year Est. Return
RA
Ritter Alpha New York $4.78M AUM
CGA
Compound Global Advisors Mercer Island, Washington $3.22M AUM 30.08% 1-Year Est. Return
HFA
Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return
ABA
American Beacon Advisors Irving, Texas $5.08M AUM 20.11% 1-Year Est. Return
UOMF
University of Maryland Foundation Adelphi, Maryland $5.1M AUM 10.69% 1-Year Est. Return

Caxton Corporation's Q3 2025 Portfolio in Review

As of Q3 2025, Caxton Corporation held 12 positions worth $22.9M, up 132% from $9.85M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Caxton Corporation deployed $3.29M of net new capital in Q3 2025, opening 1 new position and adding to 4 existing holdings. Its largest new stake was SAB Biotherapeutics: 10,935 shares worth $22K.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 82% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Definium Therapeutics, an estimated $65.9K trimmed.

  • Caxton Corporation's largest Q3 2025 buy was SAB Biotherapeutics: 10,935 shares worth $22K.
  • Caxton Corporation added most to Rezolute in Q3 2025, an estimated $2.55M increase.
  • Caxton Corporation's biggest Q3 2025 reduction was Definium Therapeutics, cutting an estimated $65.9K.
  • Caxton Corporation's ten largest holdings make up 100% of its $22.9M portfolio in Q3 2025.
  • Caxton Corporation opened 1 new position and closed 0 in Q3 2025.
  • Caxton Corporation's portfolio value rose 132% quarter-over-quarter to $22.9M.

Based on Caxton Corporation's 13F filing for Q3 2025, filed 14 Nov 2025.